Navigation Links
Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
Date:3/13/2008

http://www.nilethera.com.

Contact:

Daron Evans

Chief Financial Officer

Nile Therapeutics, Inc.

510-281-7700

info@nilethera.com

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section of our Prospectus filed pursuant to Rule 424(b)(3) of the Securities Act of 1933, as amended, with the Securities and Exchange Commission on November 15, 2007. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

STATEMENTS OF OPERATIONS

Three Months Ended Twelve Months Ended

December 31, 2007 December 31, 2007

Grant income -
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
2. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
3. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
4. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
5. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
6. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
7. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
8. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
9. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
10. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Hussey Copper , ... 29 antimicrobial copper, announces Gilmour Academy Ice Arena,s ... first EPA-registered antimicrobial solid touch surface to help protect ... reasonably priced surface that kills greater than 99.9% of ... exposure. 1 , ...
(Date:9/17/2014)... FRANCISCO, Calif. , Sept. 17, 2014 ... a molecular diagnostics company pioneering the field of molecular ... to chief operating officer. Mr. Hall joined ... the company,s commercial entry into endocrinology. Since 2012, he ... as well as managed care and billing functions. As ...
(Date:9/17/2014)... Beckman Coulter , a global ... has renewed its agreement with Personify for ... agreement, Personify will continue to streamline the Beckman Coulter ... analytics, including time-to-fill, time-to-source and a deep reduction to ... Personify was based on the success of our partnership ...
(Date:9/17/2014)... September 17, 2014 NASA’s MESSENGER has ... Engineering Corporation is proud to have one of its ... MESSENGER mission is a scientific investigation of the planet ... be sent there, and has provided a vast amount ... V27200 family of latch valves utilize solenoids that also ...
Breaking Biology Technology:Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3
... Regulus Therapeutics Inc ., a biopharmaceutical company leading the ... announced that it has identified a third microRNA target ... milestone payment from GSK. This selection represents another significant ... which is focused on the discovery and development of ...
... , Daval International announced the ... double blind Phase II,Study, Treating Patients with Bladder ... Standard clinical,measures and assessment scores recorded on patients ... be used to investigate safety,efficacy and response to ...
... ReSearch Pharmaceutical Services, Inc. (RPS), a next ... clinical development solutions to the biopharmaceutical and medical ... to its Operational and Senior Management team.   ... Chief Information Officer and Executive Vice President, Clinical ...
Cached Biology Technology:Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 3Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 4Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis 2Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis 3RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 2RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 3
(Date:9/17/2014)... of Oncology-Bellvitge Biomedical Research Institute (ICO-IDIBELL), led by ... in normal accompanying cells in colorectal tumors. Analysis ... colorectal tumors, predict the evolution of the patient ... relapses. , Biomarkers , Colorectal ... considering both sexes. About 30,000 new cases are ...
(Date:9/17/2014)... growing significantly faster since the 1960s. The typical development ... they have accelerated -- by as much as 70 ... out by scientists from Technische Universitt Mnchen based on ... continuously observed since 1870. Their findings were published recently ... "forest dieback" was a hot topic, with the very ...
(Date:9/16/2014)... The risk of severe maternal morbidity amongst women ... suggests a new study published today (17 September) ... and Gynaecology . , Australians generally enjoy high ... that health disparities exist, in particular between indigenous ... aimed to explore the independent impact of socioeconomic ...
Breaking Biology News(10 mins):Five genes to predict colorectal cancer relapses 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3
... investigated the rates of evolution of the two key characteristics ... order to fly, hulking meat-eating dinosaurs had to shrink in ... wings. "We were really surprised to discover ... at the origin of Paraves," said Mr Puttick of Bristol,s ...
... subtype of innate lymphoid cells in human spleen essential ... the prestigious journal Nature Immunology , clears the ... more efficient vaccines against encapsulated bacteria, considered highly virulent., ... research group at IMIM (Institut Hospital del Mar d,Investigacions ...
... discovered a ,microbial Pompeii, preserved on the teeth of ... discovery is the dental calculus (plaque) which preserves bacteria ... teeth, effectively creating a mineral tomb for microbiomes. ... oral cavity carries numerous opportunistic pathogens and that periodontal ...
Cached Biology News:New insights into the origin of birds 2Researchers have identified a novel immunological mechanism of great importance for vaccine developm 2Scientists unlock a 'microbial Pompeii' 2Scientists unlock a 'microbial Pompeii' 3
TEMPLIPHI HT SEQ AMPL KIT, 1 EA. Category: Sequencing Template Amplification....
This Malachite Green Phosphate Detection Kit...
Request Info...
1+ mg expected yield of purified protein, expressed in insect cells - excludes cDNA...
Biology Products: